RxDoctor Payments Data

Shiva Gangadhar, MD

Physical Medicine & Rehabilitation · Indianapolis, INNPI 1043585946

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 41.9% of the total. Reporting peaked in 2019 at $333 and has fallen 57.8% since, to $141 in 2025.

$1,223in general payments, 2019–2025

Across 77 payments — averaging $15.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$512
  • Novartis$179
  • E.r. Squibb & Sons, L.L.C.$100
  • Pfizer$55
  • Scilex Pharmaceuticals Inc.$47
  • Avanir Pharmaceuticals, Inc.$41
  • plus $288 from 13 others

What the payments were for

  • Food & beverage$1,223100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,223 in reported general payments places this provider in the 70th percentile of 140 physical medicine & rehabilitation providers in Indiana.

See all physical medicine & rehabilitation providers in Indiana

Medicare billing

Part B allowed, 2024
$287,734
Medicare patients
672
Services billed
2,921

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban70$39,986
OxycontinOxycodone Hcl30$23,182
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen549$21,236
Xtampza ErOxycodone Myristate26$15,973
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen517$12,263
LyricaPregabalin12$6,989
LinzessLinaclotide12$6,255
ButransBuprenorphine11$6,146
Gabapentin238$3,829
Fentanyl35$3,817
Cyclobenzaprine Hcl169$3,559
Pregabalin110$3,375
Diclofenac Sodium36$2,592
Morphine Sulfate ErMorphine Sulfate74$2,278
Oxycodone Hcl115$1,973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Lyrica$55$46,97582 claims
Collegium Pharmaceutical, Inc.Xtampza Er$39$15,97326 claims
AbbVieLinzess$512$6,25512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 140 physical medicine & rehabilitation providers in Indiana.

Other physical medicine & rehabilitation in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →